



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Hala
Donald R. Banowit
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longsworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Michelle K. Holoubek
Marsha A. Rose

Christopher J. Walsh
W. Blake Coblenz*
James J. Pohl*
Young Tang
John I. Haran*
Mark W. Rygiel
Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
*Admitted only in Maryland
+Admitted only in Virginia
#Practice Limited to Federal Agencies

January 19, 2007

IPAD\$ CC
WRITER'S DIRECT NUMBER:
(202) 772-8822

INTERNET ADDRESS:
SCARROLL@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1646

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/774,622; Filed: February 10, 2004
For: **Death Domain Containing Receptor 5**
Inventors: NI *et al.*
Our Ref: 1488.131000D/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover:
IDS fee under 37 C.F.R. § 1.17(p);
2. Fourth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(c);
3. Form PTO/SB/08A (2 sheets) listing 28 documents (AI2-AK4 and AL5-AN5);
4. Form PTO/SB/08B (16 sheets) listing 142 documents (AT34-AT81);
5. Copies of cited documents (AL5- AN5 and AT34-AR81); and
6. One (1) Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
January 19, 2007
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

SAC/rss
Enclosures

632743_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ni *et al.*

Appl. No.: 10/774,622

Filed: February 10, 2004

For: **Death Domain Containing
Receptor 5**

Confirmation No.: 9532

Art Unit: 1646

Examiner: Kaufman, Claire M.

Atty. Docket: 1488.131000D/EJH/SAC

**Fourth Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(c).**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Information Disclosure Statement filed on November 4, 2005 in connection with the above-captioned application.

Copies of **AL5** to **AN5** and **AT34** to **AR81** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent publications, documents **AI2** to **AK4** cited on the attached IDS Form PTO/SB/08A, are not submitted. In addition, a copy of documents **AS81** and **AT81** are not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or

01/23/2007 MAHMED1 00000002 10774622

01 FC:1806

180.00 0P

portion of the application which caused it to be listed) is sua sponte waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following related U.S. Patent Applications:

U.S. Patent Application No. 10/979,831, inventors Ni *et al.*, filed November 3, 2004, published as US2005/0233958 A1, cited herein as **AE4**;

U.S. Provisional Patent Application No. 60/040,846, inventors Ni *et al.*, filed March 17, 1997, not published, cited herein as **AT75**;

U.S. Provisional Patent Application No. 60/054,021, inventors Ni *et al.*, filed July 29, 1997, not published, cited herein as **AS76**;

U.S. Provisional Patent Application No. 60/132,498, inventors Ni *et al.*, filed May 4, 1999, not published, cited herein as **AR77**;

U.S. Provisional Patent Application No. 60/133,238, inventors Ni *et al.*, filed May 7, 1999, not published, cited herein as **AS77**; and

U.S. Provisional Patent Application No. 60/148,939, inventors Ni *et al.*, filed August 13, 1999, not published, cited herein as **AT77**.

In addition, the Examiner's attention is directed to the following Interference Nos. 105,361; 105,240; 105,380 and 105,381 which are directed to related subject matter. For the convenience of the Examiner, Applicants have provided a copy of the motion lists filed by each party in Interference Nos. 105,361; 105,240; 105,380 and 105,381 cited

herein as documents **AR78** to **AT80**. Applicants have also cited patents, patent applications, and non-patent references listed in the Exhibit Lists for Interference Nos. 105,361; 105,240; 105,380 and 105,381 that have not already been made of record in the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an


action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: January 22, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

623131v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/774,622
				Filing Date	February 10, 2004
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	1	of	2	Attorney Docket Number	1488.131000D/EJH/SAC

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
	AI2	4,411,993	10/25/1983	Gillis	
	AJ2	5,565,332	10/15/1996	Hoogenboom <i>et al.</i>	
	AK2	5,910,574	06/08/1999	Presta <i>et al.</i>	
	AA3	6,072,047	06/06/2000	Rauch <i>et al.</i>	
	AB3	6,252,050 B1	06/26/2001	Ashkenazi <i>et al.</i>	
	AC3	6,265,556 B1	07/24/2001	Reed <i>et al.</i>	
	AD3	6,342,369 B1	01/29/2002	Ashkenazi	
	AE3	6,455,040 B1	09/24/2002	Wei <i>et al.</i>	
	AF3	6,569,642 B1	05/27/2003	Rauch <i>et al.</i>	
	AG3	6,635,743 B1	10/21/2003	Ebner <i>et al.</i>	
	AH3	6,642,358 B1	11/04/2003	Rauch <i>et al.</i>	
	AI3	6,689,744 B2	02/10/2004	Gao <i>et al.</i>	
	AJ3	2002/0004227 A1	01/10/2002	Ashkenazi <i>et al.</i>	
	AK3	2002/0150985 A1	10/17/2002	Adams <i>et al.</i>	
	AA4	2003/0004313 A1	01/02/2003	Ashkenazi	
	AB4	2003/0017161 A1	01/23/2003	Ashkenazi <i>et al.</i>	
	AC4	2003/0148455 A1	08/07/2003	Adams <i>et al.</i>	
	AD4	2004/0009552 A1	01/15/2004	Adams <i>et al.</i>	
	AE4	2005/0233958 A1	10/20/2005	Ni <i>et al.</i>	
	AF4	2005/0282230 A1	12/22/2005	Ashkenazi <i>et al.</i>	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		
	AL5	WO 89/05859 A1	06/29/1989	The Upjohn Company; Regents of the University of Toledo	
	AM5	WO 92/01810 A1	02/06/1992	Lerner <i>et al.</i>	
	AN5	WO 03/038043 A2	05/08/2003	UAB Research Foundation	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 03/31/2007. OMB 0651-003
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
A collection of information unless it contains a valid OMB control number.

 U.S. Patent and Trademark Office for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number Filing Date First Named Inventor Art Unit Examiner Name	10/774,622 February 10, 2004 Ni, Jian 1646 KAUFMAN, Claire M.
Sheet	2	of	2	Attorney Docket Number 1488.131000D/EJH/SAC	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

619366v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **'**Applicant's unique citation designation number (optional). **²** See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **³** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **⁶** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known
**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1

of

16

Application Number

10/774,622

Filing Date

July 22, 2004

First Named Inventor

Ni, Jian

Art Unit

1646

Examiner Name

KAUFMAN, Claire M.

Attorney Docket Number

1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AT34	Ahn, E.-Y., <i>et al.</i> , "Calmodulin Binding to the Fas Death Domain," <i>J. Biol. Chem.</i> 279:5661-5666, JBC Papers in Press (February 2004)	
	AR35	Alderson, M.R., <i>et al.</i> , "Regulation of apoptosis and T cell activation by Fas-specific mAb," <i>Int. Immunol.</i> 6:1799-1806, Oxford University Press (1994)	
	AS35	Altschul, S.F., <i>et al.</i> , "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215:403-410, Academic Press (1990)	
	AT35	Andrés, M., <i>et al.</i> , "Characterization of specific corticosterone binding sites in adrenal cortex plasma membrane and their localization by autoradiographic studies," <i>Cell. Mol. Life. Sci.</i> 53:673-680, Birkhauser Verlag (September 1997)	
	AR36	Armitage, R.J., <i>et al.</i> , "Molecular and biological characterization of a murine ligand for CD40," <i>Nature</i> 357:80-82, Nature Publishing Group (1992)	
	AS36	Ashkenazi, A., <i>et al.</i> , "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," <i>Proc. Natl. Acad. Sci. USA</i> 88:10535-10539, National Academy of Sciences (1991)	
	AT36	Beg, A.A. and Baltimore, D., "An Essential Role for NF- κ B in Preventing TNF- α -Induced Cell Death," <i>Science</i> 274:782-784, American Association for the Advancement of Science (November 1996)	
	AR37	Bennett, B.D., <i>et al.</i> , "Cloning and Characterization of HTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily," <i>J. Biol. Chem.</i> 269:14211-14218, American Society for Biochemistry and Molecular Biology, Inc. (1994)	
	AS37	Bodmer, J.-L., <i>et al.</i> , "TRAIL receptor-2 signals apoptosis through FADD and caspase-8," <i>Nat. Cell. Biol.</i> 2:241-243, Macmillian Magazines Ltd. (April 2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	2	of	16	Filing Date	July 22, 2004
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
	AT37	Boldin, M.P., <i>et al.</i> , "Self-association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects," <i>J. Biol. Chem.</i> 270:387-391, American Society for Biochemistry and Molecular Biology, Inc. (1995)			
	AR38	Bridgman, J.T., <i>et al.</i> , "All in the family: evolutionary and functional relationships among death receptors," <i>Cell Death Differ.</i> 10:19-25, Nature Publishing Company (January 2003)			
	AS38	Brutlag, D.L., <i>et al.</i> , "Improved sensitivity of biological sequence database searches," <i>Comput. Appl. Biosci.</i> 6:237-245, Oxford University Press (1990)			
	AT38	Carter, B.D. and Lewin, G.R., "Neurotrophins Live or Let Die: Does p75 ^{NTR} Decide?," <i>Neuron</i> 18:187-190, Cell Press (February 1997)			
	AR39	Casaccia-Bonelli, P., <i>et al.</i> , "Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75, <i>Nature</i> 383:716-719, Nature Publishing Group (October 1996)			
	AS39	Cervantes-Acosta, G., <i>et al.</i> , "Human Jurkat lymphocytes clones differ in their capacity to support productive human immunodeficiency virus type 1 multiplication," <i>J. Virol. Methods.</i> 92:207-213, Elsevier/North-Holland Biomedical Press (April 2001)			
	AT39	Chapman, B.S., "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-1 and Fas," <i>FEBS Lett.</i> 374:216-220, Elsevier Science Ltd. (1995)			
	AR40	Chuntharapai, A., <i>et al.</i> , "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> 166:4891-4898, American Association of Immunologists (April 2001)			
	AS40	Cifone, M.G., <i>et al.</i> , "Apoptotic Signaling through CD95 (Fas/Apo-1) Activates an Acidic Sphingomyelinase," <i>J. Exp. Med.</i> 177:1547-1552, Rockefeller University Press (1993)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	3	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
	AT40	Clancy, L., et al., "Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> 102:18099-18104, National Academy of Sciences (December 2005)			
	AR41	Clewley, J.P. and Arnold, C., "Megalign: The Multiple Alignment Module of LASERGENE," in <i>Methods in Molecular Biology, Vol. 70: Sequence Data Analysis Guidebook</i> , Swindell, S.R., eds., Humana Press Inc., Totowa, NJ, pp. 119-129 (April 1997)			
	AS41	Clodi, K., et al., "Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells," <i>Br. J. Haematol.</i> 111:580-586, Blackwell Science Ltd. (November 2000)			
	AT41	Colucci, S., et al., "T cells support osteoclastogenesis in an vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction," <i>Blood</i> 104:3722-3730, The American Society of Hematology (December 2004)			
	AR42	Cordero, O.J., et al., "Cell surface human α-L-fucosidase," <i>Eur. J. Biochem.</i> 268:3321-3331, Blackwell Science Ltd. (June 2001)			
	AS42	Cramer, S.D., et al., "A Mouse Growth Hormone-binding Protein RIA: Concentrations in Maternal Serum during Pregnancy," <i>Endocrinology</i> 130:1074-1076, Endocrine Society (1992)			
	AT42	Daniels, R.A., et al., "Expression of TRAIL and TRAIL receptors in normal and malignant tissues," <i>Cell Res.</i> 15:430-438, Institute of Biochemistry and Cell Biology (June 2005)			
	AR43	Dempsey, P.W., et al., "The signaling adaptors and pathways activated by TNF superfamily," <i>Cytokine Growth Factor Rev.</i> 14:193-209, Elsevier Science Ltd. (June-August 2003)			
	AS43	Devereux, J., et al., "A comprehensive set of sequence analysis programs for the VAX," <i>Nucleic Acids Res.</i> 12:387-395, IRL Press Ltd. (1984)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	4	of	16	Filing Date	July 22, 2004
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		
	AT43	Doctor, K.S., <i>et al.</i> , "The apoptosis database," <i>Cell Death Differ.</i> 10:621-633, Nature Publishing Group (June 2003)		
	AR44	Drosopoulos, K.G., <i>et al.</i> , "Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway," <i>J. Biol. Chem.</i> 280:22856-22867, JBC Papers in Press (June 2005)		
	AS44	Eischen, C.M., <i>et al.</i> , "Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions," <i>Blood</i> 90:935-943, The American Society of Hematology (August 1997)		
	AT44	Emery, J.G., <i>et al.</i> , "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> 273:14363-14367, American Society for Biochemistry and Molecular Biology, Inc. (June 1998)		
	AR45	Engelmann, H., <i>et al.</i> , Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-like Activity," <i>J. Biol. Chem.</i> 265:14497-14504, American Society for Biochemistry and Molecular Biology, Inc. (1990)		
	AS45	Espevik, T., <i>et al.</i> , "Characterization of Binding and Biological Effects of Monoclonal Antibodies Against a Human Tumor Necrosis Factor Receptor," <i>J. Exp. Med.</i> 171:415-426, Rockefeller University Press (1990)		
	AT45	Fadeel, B., <i>et al.</i> , "Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects <i>in vitro</i> ," <i>Int. Immunol.</i> 9:201-209, Oxford University Press (February 1997)		
	AR46	Feinstein, E., <i>et al.</i> , "The death domain: a module shared by proteins with diverse cellular functions," <i>Trends Biochem. Sci.</i> 20:342-344, Elsevier Trends Journals (1995)		
	AS46	Feldmann, M., <i>et al.</i> , "TNF α as a Therapeutic Target in Rheumatoid Arthritis," <i>Circ. Shock</i> 43:179-184, Wiley-Liss, Inc. (1994)		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	5	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
	AT46	Fiumara, P., <i>et al.</i> , "Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines," <i>Blood</i> 98:2784-2790, The American Society of Hematology (November 2001)				
	AR47	Frade, J.M., <i>et al.</i> , "Induction of cell death by endogenous nerve growth factor through its p75 receptor, <i>Nature</i> 383:166-168, Macmillan Magazines Ltd. (September 1996)				
	AS47	Georgakis, G.V., <i>et al.</i> , "Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death," <i>Br. J. Haematol.</i> 130:501-510, Blackwell Publishing Ltd. (August 2005)				
	AT47	Gong, B. and Almasan, A., "Apo2 Ligand/TNF-related Apoptosis-inducing Ligand and Death Receptor 5 Mediate the Apoptotic Signaling Induced by Ionizing Radiation in Leukemic Cells," <i>Cancer Res.</i> 60:5754-5760, American Association for Cancer Research (October 2000)				
	AR48	Griffith, T.S., <i>et al.</i> , "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> 162:2597-2605, American Association of Immunologists (March 1999)				
	AS48	Guo, F., <i>et al.</i> , "Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells," <i>Cancer Res.</i> 64:2580-2589, American Association for Cancer Research (April 2004)				
	AT48	Headon, D.J., <i>et al.</i> , "Gene defect in ectodermal dysplasia implicates a death domain adapter in development," <i>Nature</i> 414:913-916, Nature Publishing Company (December 2001)				
	AR49	Herdegen, T., <i>et al.</i> , "Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury," <i>J. Neurosci.</i> 18:5124-5135, Society for Neuroscience (July 1998)				
	AS49	Hess, S. and Engelmann, H., "A Novel Function of CD40: Induction of Cell Death in Transformed Cells," <i>J. Exp. Med.</i> 183:159-167, The Rockefeller University Press (January 1996)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	6	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
	AT49	Hiebert, S.W., <i>et al.</i> , "Cell Surface Expression and Orientation in Membranes of the 44-Amino-Acid SH Protein of Simian Virus 5," <i>J. Virol.</i> 62:2347-2357, American Society for Microbiology (1988)				
	AR50	Higgins, D.G. and Sharp, P.M., "CLUSTAL: a package for performing multiple sequence alignment on a microcomputer," <i>Gene</i> . 73:237-244, Elsevier Science Publishers B.V. (1988)				
	AS50	Hofmann, K. and Tschopp, J., "The death domain motif found in Fas (Apo-1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance," <i>FEBS Lett.</i> 371:321-323, Elsevier Science B.V. (1995)				
	AT50	Hsu, H. <i>et al.</i> , "The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF-κB Activation," <i>Cell</i> 81:495-504, Cell Press (1995)				
	AR51	Huisman, C., <i>et al.</i> , "Paclitaxel Triggers Cell Death Primarily via Caspase-independent Routes in the Non-Small Cell Lung Cancer Cell Line NCI-H460," <i>Clin. Cancer Res.</i> 8:596-606, The Association (February 2002)				
	AS51	Ibrahim, S.M., <i>et al.</i> , "Pancreatic Adenocarcinoma Cell Lines Show Variable Susceptibility to TRAIL-Mediated Cell Death," <i>Pancreas</i> 23:72-79, Lippincott Williams & Wilkins (July 2001)				
	AT51	Ichikawa, K., <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> 7:954-960, Nature Publishing Company (August 2001)				
	AR52	Itoh, N., <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> 66:233-243, Cell Press (1991)				
	AS52	Itoh, N. and Nagata, S., "A Novel Protein Domain Required for Apoptosis," <i>J. Biol. Chem.</i> 268:10932-10937, American Society for Biochemistry and Molecular Biology, Inc. (1993)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	7	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
	AT52	Jang, Y.-J., <i>et al.</i> , "Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities," <i>Cancer Lett.</i> 194:107-117, Elsevier Science Ltd. (May 2003)				
	AR53	Johnson, N.L., <i>et al.</i> , "Signal Transduction Pathways Regulated by Mitogen-activated/Extracellular Response Kinase Kinase Induce Cell Death," <i>J Biol. Chem.</i> 271:3229-3237, The American Society for Biochemistry and Molecular Biology (February 1996)				
	AS53	Kitson, J., <i>et al.</i> , "A death-domain-containing receptor that mediates apoptosis," <i>Nature</i> 384:372-375, Macmillan Magazines Ltd. (November 1996)				
	AT53	Köhler, G. and Milstein, C., "Continuous cultures of fused cells secreting antibody of predefines specificity," <i>Nature</i> 256:495-497, Nature Publishing Group (1975)				
	AR54	LeBlanc, H.N. and Ashkenazi, A., "Apo2L/TRAIL and its death and decoy receptors," <i>Cell Death Differ.</i> 10:66-75, Nature Publishing Group (July 2003)				
	AS54	Liu, Y.-J., <i>et al.</i> , "Mechanism of antigen-driven selection in germinal centres," <i>Nature</i> 342:929-931, Nature Publishing Company (1989)				
	AT54	Liu, Z.-G., <i>et al.</i> , "Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death," <i>Cell</i> 87:565-576, Cell Press (November 1996)				
	AR55	Lum, J.J., <i>et al.</i> , "Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L," <i>J. Virol.</i> 75:11128-11136, American Society for Microbiology (November 2001)				
	AS55	Lum, J.J., <i>et al.</i> , "Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions," <i>AIDS</i> 19:1125-1133, Lippincott Williams & Wilkins (July 2005)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	8	of	16	Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
	AT55	Ma, Y., <i>et al.</i> , "Analysis of TRAIL receptor expression using anti-TRAIL death receptor-5 monoclonal antibodies," <i>Chin. Med. J.</i> 116:947-950, Chinese Medical Association (June 2003)			
	AR56	Mackay, F., <i>et al.</i> , "Lymphotoxin β Receptor Triggering Induces Activation of the Nuclear Factor $\kappa\beta$ Transcription Factor in Some Cell Types," <i>J. Biol. Chem.</i> 271:24934-24938, The American Society for Biochemistry and Molecular Biology, Inc. (October 1996)			
	AS56	Maeda, T., <i>et al.</i> , "A Simple and Rapid Method for the Preparation of Plasma Membranes," <i>Biochim. Biophys. Acta.</i> 731:115-120, Elsevier Science Publishers B.V. (1983)			
	AT56	Maini, R.N., <i>et al.</i> , "Targeting TNF α for the therapy of rheumatoid arthritis," <i>Clin. Exp. Rheumatol.</i> 12/S11:S63-S66, Clinical And Experimental Rheumatology S.A.S. (1994)			
	AR57	Mapara, M.Y., <i>et al.</i> , "APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression," <i>Eur. J. Immunol.</i> 23:702-708, VCH Verlagsgesellschaft mbH (1993)			
	AS57	Marini, P., <i>et al.</i> , "Molecular requirements for the combined effects of TRAIL and ionising radiation," <i>Radiother. Oncol.</i> 68:189-198, Elsevier Ireland Ltd. (August 2003)			
	AT57	Mark, M.R., <i>et al.</i> , "rse, a Novel Receptor-type Tyrosine Kinase with Homology to Axl/Ufo, Is Expressed at High Levels in the Brain," <i>J. Biol. Chem.</i> 269:10720-10728, American Society for Biochemistry and Molecular biology, Inc. (1994)			
	AR58	Marsters, S.A., <i>et al.</i> , "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF- κ B," <i>Curr. Biol.</i> 6:1669-1676, Current Biology Ltd. (December 1996)			
	AS58	Matsuda, T., <i>et al.</i> , "Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines," <i>J. Virol.</i> 79:1367-1378, American Society for Microbiology (February 2005)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	9	of	16	Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ²
	AT58	Matysiak, M., et al., "TRAIL induces death of human oligodendrocytes isolated from adult brain," <i>Brain</i> 125:2469-2480, Oxford University Press (November 2002)			
	AR59	Moldawer, L.L., "Interleukin-1, TNF α and Their Naturally Occurring Antagonists in Sepsis," <i>Blood Purif.</i> 11:128-133, S. Karger (1993)			
	AS59	Mongkolsapaya, J., et al., "Cutting Edge: Lymphocyte Inhibitor of TRAIL (TNF-Related Apoptosis-Inducing Ligand): A New Receptor Protecting Lymphocytes from the Death Ligand TRAIL," <i>J. Immunol.</i> 160:3-6, The American Association of Immunologists (January 1998)			
	AT59	Mongkolsapaya, J., et al., "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation," <i>Nat. Struct. Biol.</i> 6:1048-1053, Nature America Inc. (November 1999)			
	AR60	Mori, E., et al., "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2, <i>Cell Death Diff.</i> 11:203-207, Nature Publishing Group (February 2004)			
	AS60	Mühlenbeck, F., et al., "The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation," <i>J. Biol. Chem.</i> 275:32208-32213, American Society for Biochemistry and Molecular Biology, Inc. (October 2000)			
	AT60	Nagata, S. and Golstein, P., "The Fas Death Factor," <i>Science</i> 267:1449-1456, American Association for the Advancement of Science (1995)			
	AR61	Naismith, J.H. and Sprang, S.R., et al., "Tumor Necrosis Factor Receptor Superfamily," <i>J. Inflammation</i> 47:1-7, Wiley-Liss, Inc. (October 1996)			
	AS61	Nakai, K. and Kanehisa, M., "A Knowledge Base for Predicting Protein Localization Sites in Eukaryotic Cells," <i>Genomics</i> 14:897-911, Harcourt Brace Jovanovich (1992)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	10	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
	AT61	O'Connell, J., et al., "The Fas Counterattack: Fas-mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand," <i>J. Exp. Med.</i> 184:1075-1082, Rockefeller University Press (September 1996)				
	AR62	Oehm, A., et al., "Purification and Molecular Cloning of the APO-1 Cell Surface Antigen, a Member of the Tumor Necrosis Factor/Nerve Growth Factor Receptor Superfamily," <i>J. Biol. Chem.</i> 267:10709-10715, American Society for Biochemistry and Molecular Biology, Inc. (1992)				
	AS62	Ogasawara, J., et al., "Lethal effect of the anti-Fas antibody in mice," <i>Nature</i> 364:806-809, Nature Publishing Group (1993)				
	AT62	O'Kennedy, R. and Roben, P., "Antibody engineering: an overview," in <i>Essays in Biochemistry, Volume 26</i> , Tipton, K.F., ed., Portland Press Ltd., London, U.K., pp. 59-75 (1991)				
	AR63	Parson, W., et al., "Cancer cell line identification by short tandem repeat profiling: power and limitations," <i>FASEB J.</i> 19:434-436, Federation (January 2005)				
	AS63	Pawelec, G., et al., "Constitutive interleukin 2 production by the JURKAT human leukemic T cell line," <i>Eur. J. Immunol.</i> 12:387-392, VCH Verlagsgesellschaft (1982)				
	AT63	Pawlowski, K., et al., "From fold to function predictions: an apoptosis regulator protein BID," <i>Comp. Chem.</i> 24:511-517, Elsevier Science Ltd. (May 2000)				
	AR64	Pukac, L., et al., "HGS-ETRI, a fully human TRAIL-receptor I monoclonal antibody, induces cell death in multiple tumour types <i>in vitro</i> and <i>in vivo</i> ," <i>Br. J. Cancer</i> 92:1430-1441, Nature Publishing Group (April 2005)				
	AS64	Reed, J.C., "Mechanisms of Apoptosis," <i>Am. J. Pathol.</i> 157:1415-1430, American Society for Investigative Pathology (November 2000)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	11	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	AT64	Reed, J.C., <i>et al.</i> , "The Domains of Apoptosis: A Genomics Perspective," <i>Sci. STKE</i> re9:1-29, American Association for the Advancement of Science (June 2004)			
	AR65	Rennert, P.D., <i>et al.</i> , "Surface Lymphotoxin α/β Complex Is Required for the Development of Peripheral Lymphoid Organs," <i>J. Exp. Med.</i> 184:1999-2006, The Rockefeller University Press (November 1996)			
	AS65	Sato, T., <i>et al.</i> , "A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40," <i>FEBS Lett.</i> 358:113-118, Elsevier Science Ltd. (1995)			
	AT65	Screaton, G.R., <i>et al.</i> , "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <i>Curr. Biol.</i> 7:693-696, Current Biology Ltd. (September 1997)			
	AR66	Sheehan, K.C.F., <i>et al.</i> , "Monoclonal Antibodies specific for Murine p55 and p75 Tumor Necrosis Factor Receptors: Identification of a Novel In Vivo Role for p75," <i>J. Exp. Med.</i> 181:607-617, Rockefeller University Press (1995)			
	AS66	Simon, A.K., <i>et al.</i> , "Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 98:5158-5163, National Academy of Sciences (April 2001)			
	AT66	Söderström, T.S., <i>et al.</i> , "Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8," <i>J. Immunol.</i> 169:2851-2860, American Association of Immunologists (September 2002)			
	AR67	Sprick, M.R., <i>et al.</i> , "FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2," <i>Immunity</i> 12:599-609, Cell Press (June 2000)			
	AS67	Srivastava, R.K., "TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer," <i>Neoplasia</i> 3:535-546, BC Decker (November – December 2001)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	12	of	16	Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	AT67	Suda, T., <i>et al.</i> , "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family," <i>Cell</i> 75:1169-1178, Cell Press (1993)			
	AR68	Tewari, M. and Dixit, V.M., "Recent advances in tumor necrosis factor and CD40 signaling," <i>Curr. Opin. Genet. Dev.</i> 6:39-44, Current Biology Ltd. (February 1996)			
	AS68	Trauth, B.C., <i>et al.</i> , "Monoclonal Antibody—Mediated Tumor Regression by Induction of Apoptosis," <i>Science</i> 245:301-305, American Association for the Advancement of Science (1989)			
	AT68	Trueba, M., <i>et al.</i> , "Specific Binding Sites for Corticosterone in Isolated Cells and Plasma Membrane from Rat Liver," <i>J. Membrane Biol.</i> 120:115-124, Springer-Verlag (1991)			
	AR69	Tsubata, T., <i>et al.</i> , "B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40," <i>Nature</i> 364:645-648, Nature Publishing Company (1993)			
	AS69	Uckun, F.M., <i>et al.</i> , "Stimulation of Protein Tyrosine Phosphorylation, Phosphoinositide Turnover, and Multiple Previously Unidentified Serine/Threonine-specific Protein Kinases by the Pan-B-cell Receptor CD40/Bp50 at Discrete Development Stages of Human B-cell Ontogeny," <i>J. Biol. Chem.</i> 266:17478-17485, American Society for Biochemistry and Molecular Biology, Inc. (1991)			
	AT69	Ursini-Siegel, J., <i>et al.</i> , "TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis," <i>J. Immunol.</i> 169:5505-5513, American Association of Immunologists (November 2002)			
	AR70	Van Antwerp, D.J., <i>et al.</i> , "Suppression of TNF- α -Induced Apoptosis by NF- κ B," <i>Science</i> 274:787-789, American Association for the Advancement of Science (November 1996)			
	AS70	Walczak, H., <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (September 1997)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	13	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	AT70	Wang, C.-Y., <i>et al.</i> , TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB," <i>Science</i> 274:784-787, American Association for the Advancement of Science (November 1996)			
	AR71	Ware, C.F., <i>et al.</i> , "Apoptosis Mediated by the TNF-Related Cytokine and Receptor Families," <i>J. Cell. Biochem.</i> 60:47-55, Wiley-Liss, Inc. (January 1996)			
	AS71	Ware, C.F., <i>et al.</i> , "Tumor Necrosis Factor-Related Ligands and Receptors," in <i>The Cytokine Handbook</i> , 3 rd ed., Thomas, A.W., ed., Academic Press Limited, St. Louis, MO, pp.549-592 (July 1998)			
	AT71	Weller, M., <i>et al.</i> , "Fas/APO-1 GENE Transfer for Human Malignant Glioma," <i>Cancer Res.</i> 55:2936-2944, American Association for Cancer Research (1995)			
	AR72	Wen, J., <i>et al.</i> , "Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells," <i>Blood</i> 96:3900-3906, The American Society of Hematology (December 2000)			
	AS72	Wendling, U., <i>et al.</i> , "Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells," <i>Cell Death Diff.</i> 7:637-644, Nature Publishing Group (July 2000)			
	AT72	Wu, G.S., <i>et al.</i> , "KILLER/DR5 is DNA damage-inducible p53-regulated death receptor gene," <i>Nat. Genet.</i> 17:141-143, Nature Publishing Company (October 1997)			
	AR73	Yagita, H., <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> 95:777-783, Blackwell Publishing (October 2004)			
	AS73	Yonehara, S., <i>et al.</i> , "A Cell-killing Monoclonal Antibody (ANTI-Fas) to a Cell Surface Antigen Co-downregulated with the Receptor of Tumor Necrosis Factor," <i>J. Exp. Med.</i> 169:1747-1756, Rockefeller University Press (1989)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	14	of	16	Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	AT73	Yun, T.J., <i>et al.</i> , "OPG/FDCR-1, a TNF Receptor Family Member, Is Expressed in Lymphoid Cells and Is Up-regulated by Ligating CD40," <i>J. Immunol.</i> 161:6113-6121, American Association of Immunologists (December 1998)			
	AR74	Zhang, X.D., <i>et al.</i> , "Relation of TNF-related Apoptosis-inducing Ligand (TRAIL) Receptor and FLICE-inhibitory Protein Expression to TRAIL-induced Apoptosis of Melanoma," <i>Cancer. Res.</i> 59:2747-2753, American Association for Cancer Research (June 1999)			
	AS74	NCBI Entrez, GenBank Report, Accession No. NP_002537 (February 2006)			
	AT74	Copy of U.S. Non-Provisional Application No. 08/857,216, inventors Ashkenazi, A.J., <i>et al.</i> , filed May 15, 1997 (NOT PUBLISHED)			
	AR75	Copy of U.S. Non-Provisional Application No. 09/020,746, inventors Ashkenazi, A.J., <i>et al.</i> , filed February 9, 1998 (NOT PUBLISHED)			
	AS75	Copy of U.S. Application No. 09/378,045, inventor Rauch, C., filed August 20, 1999 (NOT PUBLISHED)			
	AT75	Copy of U.S. Provisional Application No. 60/040,846, inventors Ni, J., <i>et al.</i> , filed March 17, 1997 (NOT PUBLISHED)			
	AR76	Copy of U.S. Provisional Application No. 60/046,615, inventor Ashkenazi, A.J., <i>et. al.</i> , filed May 15, 1997 (NOT PUBLISHED)			
	AS76	Copy of U.S. Provisional Application No. 60/054,021, inventors Ni, J., <i>et al.</i> , filed July 29, 1997 (NOT PUBLISHED)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/774,622
Sheet	15	of	16	Filing Date	July 22, 2004
				First Named Inventor	NI, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
				Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	AT76	Copy of U.S. Provisional Application No. 60/072,481, inventors Chuntharapai, A., et al., filed January 26, 1998 (NOT PUBLISHED)		
	AR77	Copy of U.S. Provisional Application No. 60/132,498, inventors Ni, J., et al., filed May 4, 1999 (NOT PUBLISHED)		
	AS77	Copy of U.S. Provisional Application No. 60/133,238, inventors Ni, J., et al., filed May 7, 1999 (NOT PUBLISHED)		
	AT77	Copy of U.S. Provisional Application No. 60/148,939, inventors Ni, J., et al., filed August 13, 1999 (NOT PUBLISHED)		
	AR78	Ni et al., "Ni List of Intended Motions," October 20, 2005-Patent Interference No. 105,361		
	AS78	Ni et al., "Ni Clarification of List of Intended Motions," October 21, 2005-Patent Interference No. 105,361		
	AT78	Ni et al., "Ni List of Intended Motions," October 27, 2005-Patent Interference No. 105,240		
	AR79	Ni et al., "Ni List of Intended Motions," November 17, 2005-Patent Interference No. 105,380		
	AS79	Ni et al., "Ni List of Intended Motions," November 17, 2005-Patent Interference No. 105,381		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/774,622
				Filing Date	July 22, 2004
				First Named Inventor	Ni, Jian
				Art Unit	1646
				Examiner Name	KAUFMAN, Claire M.
Sheet	16	of	16	Attorney Docket Number	1488.131000D/EJH/SAC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AT79	Adams <i>et al.</i> , "Adams Motions List," October 20, 2005- Patent Interference No. 105,361	
	AR80	Rauch <i>et al.</i> , "Rauch List of Intended Substantive Motions," October 27, 2005- Patent Interference No. 105,240	
	AS80	Rauch <i>et al.</i> , "Rauch List of Intended Substantive Motions," November 23, 2005- Patent Interference No. 105,380	
	AT80	Rauch <i>et al.</i> , "Rauch List of Intended Substantive Motions," November 23, 2005- Patent Interference No. 105,381	
	AR81	U.S. Provisional Application No. 60/074,119, inventor Ashkenazi, A.J., filed February 9, 1998 (NOT PUBLISHED)	
	AS81	U.S. Non-Provisional Application No. 11/455,062, inventor Ashkenazi, A.J., filed June 15, 2006 (NOT PUBLISHED)	
	AT81	U.S. Non-Provisional Application No. 11/483,978, inventors Adams, C., filed July 11, 2006 (NOT PUBLISHED)	

619368v1

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.